RIVAROXABAN IN PATIENTS STABILIZED AFTER A ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. RESULTS FROM THE ATLAS ACS-2–TIMI-51 TRIAL

MLA

J. L. Mega, et al. “Rivaroxaban in Patients Stabilized After a St-Segment Elevation Myocardial Infarction. Results from the Atlas Acs-2–Timi-51 Trial.” Рациональная Фармакотерапия в Кардиологии, vol. 10, no. 2, Sept. 2015, pp. 245–52. EBSCOhost, https://doi.org/10.1234/1819-6446-2014-2-245-252.

APA

J. L. Mega, E. Braunwald, S. A. Murphy, A. N. Plotnikov, P. Burton, R. G. Kiss, A. Parkhomenko, M. Tendera, P. Widimsky, & C. M. Gibson. (2015). Rivaroxaban in Patients Stabilized After a St-Segment Elevation Myocardial Infarction. Results from the Atlas Acs-2–Timi-51 Trial. Рациональная Фармакотерапия в Кардиологии, 10(2), 245–252. https://doi.org/10.1234/1819-6446-2014-2-245-252

Chicago

J. L. Mega, E. Braunwald, S. A. Murphy, A. N. Plotnikov, P. Burton, R. G. Kiss, A. Parkhomenko, M. Tendera, P. Widimsky, and C. M. Gibson. 2015. “Rivaroxaban in Patients Stabilized After a St-Segment Elevation Myocardial Infarction. Results from the Atlas Acs-2–Timi-51 Trial.” Рациональная Фармакотерапия в Кардиологии 10 (2): 245–52. doi:10.1234/1819-6446-2014-2-245-252.